Hierarchical Clustering of Activated Proteins in the PI3K and MAPK Pathways in ER-positive, HER2-negative Breast Cancer With Potential Therapeutic Consequences

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0221-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2013English

Differential Expression and Function of the Endogenous Lactate Receptor, GPR81, in ER��-positive/HER2-positive Epithelial vs. Post-Emt Triple-Negative Mesenchymal Breast Cancer Cells

Journal of Cancer Metastasis and Treatment
2019English

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways

PLoS ONE
Multidisciplinary
2010English

Targeted Therapeutic Options and Future Perspectives for HER2-positive Breast Cancer

Signal Transduction and Targeted Therapy
Cancer ResearchGenetics
2019English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Distinct Genes Related to Drug Response Identified in ER Positive and ER Negative Breast Cancer Cell Lines

PLoS ONE
Multidisciplinary
2012English

Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Clinical Drug Investigation
MedicinePharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy